Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470054 · ClinicalTrials.gov registry record · Phase 2
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00470054: Completed Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00470054 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, below the 174-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470054, a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Percentage of patients who were alive and progression free at 6-weeks. The 6-week progression free survival was estimated using the Kaplan Meier method. Progressive Disease was defined by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria as 20% increase in sum of longest diameter of target lesions.
Conditions Studied
Interventions
- DRUG dasatinib
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00470054 record still lists
NCT00470054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 174-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which dasatinib is the first listed.
NCT00470054 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00470054 about?
NCT00470054 is a clinical study titled "Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer". This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00470054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-04. Estimated completion is 2013-04.
What conditions does trial NCT00470054 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer, Recurrent Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer.
What interventions are being tested in trial NCT00470054?
The interventions under investigation include: dasatinib (DRUG).
Who is sponsoring clinical trial NCT00470054?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00470054 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00470054's enrollment target sits among peer trials
44 18th of 25 higher than 8 of 25 other Extensive-stage Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
RECRUITING · Phase 2
-
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
ACTIVE NOT RECRUITING · Phase 2
-
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia